paediatric Archives -

News/ News/ Patients

COVID jabs now offered to all children aged 5 to 11 across UK

Phil Taylor BioNTech, Comirnaty, COVID-19, COVID-19 vaccine, paediatric, Pfizer, UK 0 Comment

England and Northern Ireland have followed Wales and Scotland in offering healthy children aged between five and 11

COVID jabs now offered to all children aged 5 to 11 across UK

https://pharmaphorum.com/news/covid-jabs-now-offered-to-all-children-aged-5-to-11-across-uk/

Market Access/ News/ News

NHS signs deal with Orchard for pricey Libmeldy gene therapy

Phil Taylor gene therapy, HEOR, Libmeldy, NHS, NICE, Orchard Therapeutics, paediatric, rare disease 0 Comment

NHS England has agreed a confidential deal with Orchard Therapeutics that will allow access to Libmeldy – a

NHS signs deal with Orchard for pricey Libmeldy gene therapy

https://pharmaphorum.com/news/nhs-signs-deal-with-orchard-for-pricey-libmeldy-gene-therapy/

News/ News/ Patients

EU authorises first COVID-19 vaccine for 5 to 11 year olds

Phil Taylor BioNTech, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, paediatric, Pfizer 0 Comment

The European Medicines Agency (EMA) has approved Pfizer and BioNTech’s COVID-19 vaccine Comirnaty for children between the ages

EU authorises first COVID-19 vaccine for 5 to 11 year olds

https://pharmaphorum.com/news/eu-approves-first-covid-19-vaccine-for-5-to-11-year-olds/

News/ News/ Patients

US backs COVID jabs for young kids – should others follow?

Phil Taylor BioNTech, CDC, coronavirus, COVID-19, COVID-19 vaccine, paediatric, Pfizer 0 Comment

The US is now pressing ahead with plans to extend its COVID-19 vaccination campaign to younger children aged

US backs COVID jabs for young kids – should others follow?

https://pharmaphorum.com/news/us-backs-covid-jabs-for-young-kids-should-others-follow/

Market Access/ News/ News

FDA delays review of Moderna COVD jab in adolescents

Phil Taylor BioNTech, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, Moderna, mRNA, paediatric, Pfizer, safety 0 Comment

The FDA has said it needs more time to review Moderna’s application for emergency use of its COVID-19

FDA delays review of Moderna COVD jab in adolescents

https://pharmaphorum.com/news/fda-delays-review-of-moderna-covd-jab-in-adolescents/

News/ News/ Patients

FDA advisors mull use of Pfizer/BioNTech COVID-19 jab in kids

Phil Taylor BioNTech, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, Moderna, paediatric, Pfizer 0 Comment

FDA advisors will meet later today discuss the possibility of authorising Pfizer and BioNTech’s COVID-19 vaccine Comirnaty in

FDA advisors mull use of Pfizer/BioNTech COVID-19 jab in kids

https://pharmaphorum.com/news/fda-advisors-mull-use-of-pfizer-biontech-covid-19-jab-in-kids/

News/ News/ Patients

Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11

Phil Taylor BioNTech, Comirnaty, coronavirus, COVID-19, COVID-19 vaccine, fda, paediatric, Pfizer 0 Comment

With positive phase 2/3 results for their COVID-19 vaccine Comirnaty in hand for the five to 11 age

Pfizer, BioNTech prep low-dose COVID jab filing for kids aged 5 to 11

https://pharmaphorum.com/news/pfizer-biontech-prep-low-dose-covid-jab-filing-for-kids-aged-5-to-11/

Market Access/ News/ News

NICE backs Cosentyx’ use in thousands of children with psoriasis

Phil Taylor Cosentyx, HEOR, market access, NHS, NICE, Novartis, paediatric, psoriasis 0 Comment

NICE has recommended broadening NHS use of Novartis’ IL-17 inhibitor Cosentyx to include children aged six to 17

NICE backs Cosentyx’ use in thousands of children with psoriasis

https://pharmaphorum.com/news/nice-backs-cosentyx-use-in-thousands-of-children-with-psoriasis/

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Market Access/ News/ News

NICE rejects Orchard’s gene therapy for rare childhood disease MLD

Phil Taylor gene therapy, HEOR, Libmeldy, NICE, Orchard Therapeutics, paediatric, rare disease 0 Comment

Orchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use

NICE rejects Orchard’s gene therapy for rare childhood disease MLD

https://pharmaphorum.com/news/nice-rejects-orchards-gene-therapy-for-rare-childhood-disease-mld/

Trending

paediatric

Login